Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer.
BACKGROUND
Loss of erythrocyte membrane protein band 4.1-like 3 (EPB41L3; aliases: protein 4.1B, differentially expressed in adenocarcinoma of the lung-1 (Dal-1)) expression has been implicated in tumor progression.


OBJECTIVE
To evaluate literature describing the role of EPB41L3 in tumorigenesis and metastasis, and to consider whether targeting this gene would be useful in the treatment of prostate cancer.


METHODS
A literature review of studies describing EPB41L3 and its aliases was conducted. Online databases (NCBI, SwissProt) were also interrogated to collect further data.


CONCLUSIONS
A growing body of evidence supports a role for loss of EPB41L3 in tumor progression, including in prostate cancer. Therapeutic strategies that could be harnessed to upregulate EPB41L3 gene expression in prostate cancer cells are currently being developed.
Monash University, Centre for Cancer Research, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168, Australia.
Dominic B
DB
Bernkopf
Elizabeth D
ED
Williams
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018450:Disease Progression; D016503:Drug Delivery Systems; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000187:drug effects* / Q000378:metabolism; D008840:Microfilament Proteins; D009362:Neoplasm Metastasis / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D025521:Tumor Suppressor Proteins / Q000187:drug effects* / Q000378:metabolism
D000970:Antineoplastic Agents; C116887:EPB41L3 protein, human; D008565:Membrane Proteins; D008840:Microfilament Proteins; D025521:Tumor Suppressor Proteins